ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 075

Emapalumab Treatment Followed by Hematopoietic Stem Cell Transplantation in Systemic Juvenile Idiopathic Arthritis Complicated by Recurrent Macrophage Activation Syndrome

Claudia Bracaglia1, Manuela Pardeo1, Giulia Marucci2, Simona Riccio2, Francesco Quagliarella3, Ivan Caiello2, Giusi Prencipe2, Pietro Merli3, Franco Locatelli3 and Fabrizio De Benedetti1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Roma, Italy, 3Ospedale Pediatrico Bambino Gesù, Department of Hematology/Oncology, Cell and Gene Therapy, Roma, Italy

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: interferon, Juvenile idiopathic arthritis, macrophage activation syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Thursday, March 30, 2023

Title: Posters: Clinical and Therapeutic I

Session Type: Poster Session A

Session Time: 6:00PM-7:00PM

Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening complication of different rheumatic diseases, particularly of systemic juvenile idiopathic arthritis (sJIA).

Methods: We report the case of 17-year-old girl with sJIA complicated by recurrent severe MAS episodes who received emapalumab (anti-IFNg antibody) in two subsequent MAS episodes and then underwent an uncomplicated hematopoietic stem cell transplantation (HSCT) while receiving emapalumab and anakinra granting complete control of inflammatory activity of the underlying disease.

Results: A 13-year-old White Caucasian girl presented with fever, rash and hepato-splenomegaly. Laboratory parameters were consistent with full-blown MAS (table 1). In the absence of clear evidence of an underlining condition, a diagnosis of secondary HLH was made, treatment with high dose of intravenous (IV) methylprednisolone (mPDN) and oral cyclosporine (CYC) was started with progressive improvement. After one year, still on CYC, she presented with fever, rash and arthritis with laboratory parameters consistent with MAS (table 1). Diagnosis of sJIA complicated by MAS was made. In 24 hours, she rapidly worsened and was admitted in ICU. High dose of IV mPDN (7 pulses of 30 mg/kg/day) as well as IV CYC (5 mg/kg/day) did not yield a response. Emapalumab was started, in the NI-0501-06 trial, (6 mg/kg initial dose followed by 3 mg/kg every 3 days) for 11 infusions. Conditions progressively improved. In order to prevent flares of the underlining sJIA, anakinra (2 mg/kg/day) was started. After 2 years in clinical remission, while she receiving anakinra every other day, she presented with fever, vomiting and diarrhea. Anakinra was immediately increased to daily dosing. Stool analysis showed Salmonella infection and antibiotic therapy was started. Nevertheless, she rapidly worsened, laboratory parameters were again consistent with full-blown MAS (table 1). She required ICU admission for multiorgan failure. Anakinra was administered IV and the dose increased up to 12 mg/kg/day. IV MPDs (8 pulses of 30 mg/kg/day) as well as IV CYC (5 mg/kg/day) were started with partial response. Based on her previous response to emapalumab, emapalumab was started again (compassionate use) with marked and rapid improvement. Because of recurrent MAS episodes and particularly for their rapidly evolution, the patient underwent an ex-vivo T cell-depleted haploidentical HSCT from her mother. The conditioning regimen was based on a Thiotepa-Treosulfan-Fludarabine scheme. Emapalumab was continued 1 month after HSCT together with anakinra. The patient achieved full donor engraftment with complete donor-derived immune reconstitution after 3 months. One year after HSCT, she is in excellent clinical condition on anakinra every other day, with complete remission of sJIA/MAS, also confirmed by persistently normal levels of IL-18 and CXCL9 (table 1).

Conclusion: This case provides further evidence of the efficacy of emapalumab in MAS, of the potential benefit of HSCT in difficult to treat sJIA patients. Notably, full control of inflammatory activity with emapalumab and anakinra may help to obtain a successful HSCT and reduce the risk of rejection.

Supporting image 1Table 1. Laboratory parameters and cytokine levels during disease course.


Disclosures: C. Bracaglia: Sobi, 2, 6; M. Pardeo: SOBI, 2, 6; G. Marucci: None; S. Riccio: None; F. Quagliarella: None; I. Caiello: None; G. Prencipe: None; P. Merli: Sobi, 2; F. Locatelli: Sobi, 2; F. De Benedetti: AbbVie/Abbott, 2, Novartis, 2, Novimmune, 2, Pfizer, 2, Roche, 2, Sobi, 2.

To cite this abstract in AMA style:

Bracaglia C, Pardeo M, Marucci G, Riccio S, Quagliarella F, Caiello I, Prencipe G, Merli P, Locatelli F, De Benedetti F. Emapalumab Treatment Followed by Hematopoietic Stem Cell Transplantation in Systemic Juvenile Idiopathic Arthritis Complicated by Recurrent Macrophage Activation Syndrome [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/emapalumab-treatment-followed-by-hematopoietic-stem-cell-transplantation-in-systemic-juvenile-idiopathic-arthritis-complicated-by-recurrent-macrophage-activation-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/emapalumab-treatment-followed-by-hematopoietic-stem-cell-transplantation-in-systemic-juvenile-idiopathic-arthritis-complicated-by-recurrent-macrophage-activation-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology